Watchmaker Genomics raises $40M in Series A
BOULDER — As the life sciences industry in the area continues to bloom, Watchmaker Genomics Inc., one of the newer companies in the region has completed a Series A funding round as it prepares to ramp up its research and development capabilities and expand its workforce.
Watchmaker Genomics closed its $40 million Series A this month, bringing its fundraising total to $53.5 million since its founding in 2019. The round was led by Decheng Capital with co-investment from Eclipse Ventures.
Watchmaker develops reagents that are used in genetic testing, primarily for cancer tumor profiling. They are also used in testing inherited and…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
